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In this review, we aim to lead the readers through the historical highlights of
pathophysiological concepts and treatment of pneumonia. Understanding the aetiology,
the risk factors and the pathophysiology influenced our management approaches to
pneumonia. Pneumonia is still associated with significant morbidity and mortality, presents
in a variety of healthcare settings and imposes a considerable cost to healthcare services.
Guidelines have been issued by international and national scientific societies in order to
spread the scientific knowledge on this important disease and to improve its management.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Pneumonia has been recognized as a disease entity since
remote times, with definitions of the condition traceable in
ancient Greek, Roman, and Arabic writings. Definitive
recognition of the etiologic role of microorganisms in
pneumonia, and the identification of Streptococcus pneu-
moniae as the most common causative agent was only
achieved roughly 120 years ago. The introduction of
antibiotics has obviously modified the impact of the disease
on society, but pneumonia is still associated with consider-
able morbidity and mortality. Over the last decade,
important step forwards have been made in improving
pneumonia management through the availability of scores
for patient admission decisions, timing and choice of
empirical antibiotic treatment, and vaccination prevention
strategies. The development of international and localElsevier Ltd. All rights reserved.
50320621;
imi.it (F. Blasi).guidelines has helped condense the ever-expanding scien-
tific knowledge on pneumonia into statements and recom-
mendations of clinical use for the bedside physician. This is
certainly welcome as studies indicate that patient manage-
ment is amenable to improvement in aspects such as
hospitalization of mild pneumonia cases with low mortality
risk, lack of association between microbiological investiga-
tion and pneumonia severity, inadequate antimicrobial
treatment with over-treatment of non-severe cases, and
under-treatment of severe cases.1Epidemiology and clinical presentation
Community-acquired pneumonia (CAP) is a common health
problem that may still be life threatening in an age of wide
availability of effective antibiotic therapy. The annual
incidence rate rises from 6/1000 in the 18–39 age group to
34/1000 in people aged 75 years and over.2 Geographical
variations in incidence rates are present, with, for example,
lower rates being recorded in Southern Europe compared
to Northern countries.3 Hospital admission is deemed
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being admitted to an intensive care unit (ICU). Overall
mortality from CAP is 5–10%.4
In addition to increasing age, comorbidities have long
been recognized as risk factors for CAP.5 Currently identified
risk factors for CAP include male sex, chronic obstructive
pulmonary disease (COPD), cigarette smoking, heart dis-
ease, occupational dust exposure, and single marital
status.6
Up until the early 1940s textbooks of medicine recognized
that pneumonia could present only as lobar pneumonia or
bronchopneumonia, with the small residuum dubbed as
‘‘unresolved’’. Pneumonia has largely changed its character
from the old classical lobar pneumonia to ‘‘atypical’’ clinical
and radiological descriptions.7 In a case series in the 1950s,
Wingfield8 found ‘‘atypical’’ lobar or lobular consolidation in
over 50% of patients, with classical lobar pneumonia in less
than 10% of cases.
As from the 1980s, the classification of pneumonia based
on lists of different pathogens was abandoned in favour of a
more practical classification that helps to guide investiga-
tion, management and therapy: CAP,9 hospital-acquired (or
nosocomial) pneumonia,10 and pneumonia in the immuno-
compromised host.11
Common clinical symptoms of CAP include cough, fever,
chills, fatigue, dyspnea, rigors, and pleuritic chest pain.
Cough may be persistent and dry, or it may produce sputum
in no more than 50% of patients. Other presentations may
include headache and myalgia. Physical examination may
reveal dullness to percussion of the chest, crackles or rales
on auscultation, bronchial breath sounds.Etiology
Most studies investigating the microbiological causes of
patients with CAP involved cases admitted to hospital, with
only a limited number of studies have investigated etiology
of CAP in the community. However, available information
regarding mild CAP suggests that overall microbial etiology
is not substantially different from that of hospitalized
patients, with few important exceptions.12
Analysis of CAP etiologic studies reveals variations in
terms of the frequency of individual microorganism,
probably related to differences in studied populations
(associated with age or other risk factors), geographical
area, and the presence of intercurrent epidemics. Results
may also be biased by the use/non-use of specific samples
and microbiological methods, or primary attention devoted
to particular agents (e.g. viruses or intracellular bacteria).
Regardless of the extent of microbiological investigation,
diagnostic yield in CAP rarely reaches 60% of cases. There-
fore, in all studies, the most frequent category includes
cases with no pathogen identified. This finding is probably
attributable to multiple factors including presence of
organisms undetectable by conventional microbiological
methods, ambulatory antibiotic pretreatment, presence of
as yet unknown microorganisms, and non-infective diseases
that mimic pneumonia. Age X70 years, and presence of
cardiac or renal comorbidity have been identified as factors
associated with undetermined etiology.13 Interestingly, the
introduction of sensitive new diagnostic techniques does notappear to associate with a meaningful increase in diagnostic
yield compared to the etiologic determination rates of 40
years ago.14Etiology of out-patient pneumonia
It has been estimated that 50–80% of pneumonia cases may
be treated outside the hospital and this group therefore
constitutes the majority of patients with CAP. The most
important pathogens causing pneumonia in this setting are
Streptococcus pneumoniae, intracellular bacilli such as
Mycoplasma pneumoniae and Chlamydia pneumoniae, fol-
lowed by Haemophilus influenzae.15–20 Streptococcus pneu-
moniae is more common among older patients or those with
underlying disease whereas M. pneumoniae is more often
detected in patients younger than 50 years and without
important comorbid conditions.21 Viruses are reported to be
involved in 5–20% of cases, either as sole pathogens or as
part of a mixed infection. Influenza viruses are the agents
most commonly associated with pneumonia.22 Unlike adults,
approximately 60% of lower respiratory tract infections
maybe viral in origin in children. Incidence varies in
different age groups, reaching as much as 80% during the
first years of life and up to school age, and thereafter
decreasing to 40–50%. In many cases viral infections are
complicated by superimposed bacterial involvement. Me-
tapneumovirus is a recently described paramyxovirus, which
appears to be a potentially important viral respiratory tract
pathogen, causing pneumonia in both adults and children.23
M. pneumoniae may present cyclic epidemics every 4–7
years during which a peak incidence of 30% may be reached,
with more sporadic cases being registered at other times.24
This agent is also particularly common in younger indivi-
duals, and may be among the most common bacteria in
adolescent/young adult populations. Staphylococcus aur-
eus, Legionella and gram-negative enteric bacteria are
uncommon in disease managed outside the hospital.Etiology of hospital-treated pneumonia
Between 20% and 50% of patients with pneumonia are
hospitalized for treatment.18 Streptococcus pneumoniae is
the most commonly identified pathogen in cases of CAP,
incidence ranging from 3% to 76%.25–27 Moreover, since even
a single dose of antibiotic treatment prior to pneumonia
diagnosis may hinder pneumococcal detection, it is felt that
this organism is probably the leading cause of pneumonia of
unknown etiology.28 Bacteremia may develop in 10–20% of
cases, and this pathogen alone accounts for about two thirds
of all cases of bacteremic pneumonia cases, with mortality
rates approaching 30%,29 and rarely evolving into necrotiz-
ing pneumonia.30
H. influenzae and M. pneumoniae are frequently the
second most common pathogens, and some but not all
studies attribute a greater propensity for the former agent
among smokers and COPD patients. C. pneumoniae accounts
for 3–20% of CAP cases depending on several factors such as
setting of the studied population, age group examined, and
diagnostic methods used.31,32 The clinical course may vary
from a mild, self-limiting illness to a severe form of
pneumonia, particularly in elderly patients, and in patients
with coexisting cardiopulmonary diseases. This agent is
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agents in approximately 30% of cases.28
Among the most relevant differences between etiology of
community- and hospital-treated pneumonia is the substan-
tially higher incidence of L. pneumophila cases among the
latter. The incidence of Legionella infection in different
studies ranges from 0.5% to 6% of CAP cases in most hospital-
based series.33
Etiology of severe pneumonia
A limited number of episodes of CAP (roughly 2% of all cases)
are sufficiently severe to require admission to an ICU. Along
with Streptococcus pneumoniae, Legionella spp. are identi-
fied consistently as among the most common causative
agents of severe CAP, particularly among patients suffi-
ciently severe to require intubation.34–37 Legionella was 1 of
2 major respiratory tract pathogens in patients with CAP
who required admission to the ICU, according to 7 of 9
recent reviews.38 In terms of frequency, Streptococcus
pneumoniae and L. pneumophila are followed at a distance
by Staphylococcus aureus and gram-negative enteric bac-
teria, particularly Pseudomonas aeruginosa.39 Aspiration
pneumonia is a common cause of severe pneumonia,
particularly among alcoholics, injections drug abusers,
persons with poor dental hygiene and the elderly. Etiology
is generally polymicrobial with both Gram-positive and
Gram-negative anaerobes playing a leading role in this form
of pneumonia.40 Viral infections are uncommon, and are
mostly due to influenza virus with bacterial Streptococcus
pneumoniae or Staphylococcus aureus superinfection.
Etiology of nursing home-acquired pneumonia
Elderly residents of long-term care facilities have been
found to have a particular spectrum of pathogens. In a study
of 104 patients age 75 years and older with severe
pneumonia, El-Solh found Staphylococcus aureus (29%),
enteric gram-negative rods (15%), Streptococcus pneumo-
niae (9%), and Pseudomonas species (4%) as the most
frequent causes of nursing home-acquired pneumonia.37 In
another study of 52 long-term care residents aged 70 years
and above who failed to respond to first line antibiotics,
MRSA (33%), gram-negative enterics (24%), and Pseudomo-
nas species (14%) were the most frequent pathogens isolated
by invasive diagnostics (bronchoscopy).41 In the latter study,
72% had at least two comorbidities whereas 23% had three or
more.
Mixed infections
Mixed community-acquired lower respiratory tract infec-
tions are more common than previously recognized.42,43 In
the setting of pneumonia, polymicrobial infections are
present at all ages, although there may be important
differences. In children mixed viral–bacterial are highly
prevalent, with an increase in bacterial-atypical bacterial
co-infections after school-age that appears to persist into
adult-hood. Elderly patients, on the one hand are at risk for
Gram-negative and anaerobic polymicrobial aspiration
pneumonia, and on the other are more prone to bacterial
superinfections following influenza infection. Presentation
characteristics do not help to distinguish between mono-
microbial and polymicrobial infections, although the lattertend to be associated with greater underlying diseases and
may be linked to a more severe clinical course.
Streptococcus pneumoniae is the leading pathogen in the
etiology of CAP. It is important to bear in mind that between
16% and 45% of pneumococcal infections are mixed,
generally involving an atypical bacteria or a virus. The
potential importance of mixed infections is highlighted by
recent retrospective studies showing that combined anti-
microbial therapy that includes a macrolide, given empiri-
cally, may reduce mortality associated with bacteremic
pneumococcal pneumonia.44 Recent treatment recommen-
dations have incorporated the idea that atypical pathogen
infection should be considered in all patient groups, some-
times in the form of mixed infection.
The observed rate of mixed viral–bacterial infections in
pneumonia may also lead to treatment considerations. In
individual patients during influenza epidemics, use of rapid
detection techniques such as real-time PCR may allow the
use of effective neuraminidase inhibitors such as oseltamivir
and zanamivir with 36–48 h of symptom onset, thus reducing
the emergence of secondary bacterial complications (in-
cluding pneumonia) by up to 50%.45 On a larger scale, the
known association between influenza and excess mortality
for pneumonia underscores the importance of widespread
influenza vaccination in eligible patients as this has shown to
reduce pneumonia hospitalizations and deaths.46Diagnostic methods
The traditional microbiological approach to CAP relies on
staining or culture of easily obtainable samples such as
respiratory secretions, blood or pleural fluid. Up to about 30
years ago, additional culture methods such as mouse
intraperitoneal homogenized sputum inoculation were still
in use.14 Serological determinations are the basic method to
identify atypical bacterial and viral pathogens difficult to
grow in culture. The results of applying the above
techniques is far from optimal, with etiologic diagnosis
being reached in a minority of cases.13 The results of
diagnostic procedures such as microbiological cultures or
serological tests have delays of days to weeks and are
therefore not suitable guides to therapy in an early stage of
the disease. Concerns regarding low yield, expenses, and
delay in response have raised questions on the cost-
effectiveness of systematic use of microbiological testing
in patients with pneumonia. Furthermore, studies disagree
about the impact of laboratory based microbiological testing
on the outcome of CAP.47,48 Introduction of novel techniques
such as urinary antigen detection and nucleic acid amplifi-
cation tests allows rapid identification of a number of
causative agents, but further effort is needed to identify
rapid (almost instantaneous), easily performed, accurate,
cost-effective diagnostic tests.
There is considerable debate as to the extent of
microbiological work up that should be undertaken in
patients presenting with CAP. Arguments against microbio-
logical studies include the low yield in many reports, and the
evidence that, even in patients with severe CAP, outcome is
not improved by establishing a specific etiologic diagnosis.49
On the other hand there is a perception that the quality of
microbial studies in the context of pulmonary infections has
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decades ago, and this poses questions on whether this
change is acceptable or reversible.50 There are a number of
potential advantages in endeavoring to identify causative
agents, for individual patients, society, and in economic
terms.51 Nonetheless, performing diagnostic tests should not
result in the delay of initiation of appropriate therapy as an
increased 30-day CAP mortality was registered when
administration of the first dose of antibiotic was delayed
more than 8 h from the time of arrival in hospital, and
antibiotic treatment prior to 4 h following admission reduces
length of hospital stay.52,53
Recent guidelines have provided a series of recommenda-
tions that constitute a reasonable framework for micro-
biological investigations in CAP patients.54–57 All guidelines
recognize that the extent of microbiological work up should
vary according to the site of management of CAP, with cases
managed in the community requiring minimal assessment
compared to hospitalized patients, and subjects with severe
pneumonia admitted to the ICU deserving maximal efforts to
achieve etiological diagnosis. The Infectious Diseases So-
ciety of America (IDSA) guidelines54 place a greater
emphasis on the identification of the responsible agent to
guide antibiotic therapy as compared with other interna-
tional guidelines.55,56
In general terms, outpatients with CAP should have a
chest radiograph (whenever possible), but sputum culture
and Gram stain are generally not required outside epide-
miological surveys. Sputum examination may be considered
in patients who do present purulent sputum, particularly if
they do not respond to empirical antibiotic treatment.
All hospitalized patients with CAP should undergo chest
radiography, routine blood chemistry and blood counts, and
blood gas analysis. All guidelines recommend two sets of
blood cultures. Blood cultures have a low sensitivity and a
high specificity, and are positive in about 4–18% of untreated
CAP patients, most commonly associated with severe
illness.58 The yield is generally greater if the blood specimen
is collected prior to the patient having received antibiotic
treatment.59 Assessment of specific factors associated with
greater likelihood of positive blood culture may reduce the
overall burden of tests performed with little negative
impact on the diagnostic yield.60 Gram stain and culture
are advised if the patient is able to expectorate purulent
samples and has not received prior antibiotic therapy.61,62
This is particularly true if a drug-resistant pathogen, or an
organism not covered by usual empiric antibiotic treatment,
is suspected. Although sputum testing cannot be used to
focus initial empiric antibiotic therapy, it may be used to re-
direct treatment once results have been obtained. The
pneumococcal urinary antigen assay is considered an
acceptable test to augment standard diagnostic methods
for Streptococcus pneumoniae detection.63 Similarly, testing
for Legionella is considered appropriate in hospitalized
patients with enigmatic pneumonia, or unresponsive to
b-lactam treatment.64 A very recent study found that
addition of rapid urine antigen tests for Streptococcus
pneumoniae and L. pneumophila increased the diagnostic
yield by 17.8%.65 Thoracentesis should be performed in the
presence of significant pleural effusion, with stain, culture,
pH, and leukocyte count.66 There is some debate as to how
extensively serology should be applied to hospitalizedpatients. Serologic determinations for C. pneumoniae,
M. pneumoniae, and L. pneumophila may be considered in
patients unresponsive to b-lactam treatment, during out-
breaks, or when there is strong suspicion of an ‘‘atypical’’
pathogen on clinical radiographic, or epidemiological
grounds.
In severe CAP cases, subjects requiring admittance to an
ICU, or those failing initial empiric antibiotic all the
following are recommended: blood culture, respiratory
sample Gram stain and culture, thoracenthesis. On the
basis of local availability pneumococcal and Legionella
urinary determinations should be performed together with
serological testing for atypical pathogens and viruses. In this
setting addition of invasive techniques such as bronchoscopy
(protected brush specimen and bronchoalveolar lavage)67,68
or transthoracic needle aspiration,69 depending on local
expertise, may be of use.Hospital admission
The decision whether outpatient or inpatient management
is needed for a patient with CAP is of primary importance.
Hospital admission requirements depend on many possible
variables including disease severity, coexisting illness, risk
factors, adequate family support/home facilities, and
patient compliance to treatment. Recently, two main tools
have been put forward to objectively assess pneumonia
severity and guide admission decisions.
The pneumonia severity index (PSI) was developed in the
United States and validated on over 38,000 patients.70 The
system was primarily developed to detect patients with low
mortality risk who could de safely treated as outpatients.
Patients with CAP are stratified into one of five categories
with a score system based on age, presence of coexisting
illnesses, and vital signs. Patients in classes I–III present a
low mortality risk (o3%), whereas classes IV–V have a high
mortality risk (8–30%). These finding have been extrapolated
to guide hospital admission decisions, with inpatient
treatment suggested for higher mortality PSI classes.
Application of this score system has been shown to reduce
avoidable hospital admission without increasing mortality.71
A number of limitations have been recognized. Age affects
overall score very heavily, potentially underestimating need
for hospitalization in younger patients. The score may also
overestimate the need for hospitalization and use of
expensive resources by a heavy emphasis on age and
coexisting illnesses rather than on severity features of
pneumonia. A total of 20 variables are involved in generat-
ing the score, making the system rather cumbersome and
unfit for rapid mnemonic recall at the patient bedside.
The British Thoracic Society guidelines advocate the use
of a clinical score that identifies of a limited number of
variables (three clinical, one laboratory) recognized as
strong adverse prognostic factors for pneumonia. The
factors include age over 65, mental confusion, elevated
urea nitrogen, and respiratory rate430 breaths per minute,
condensed in the acronym CURB-65. Patients who do not
present any of the factors have been shown to have a
mortality risk close to 1%, and may be considered for
outpatient management, whereas presence of two or more
adverse factors suggest the need for hospital admission.72,73
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PSI and measures pneumonia disease severity more directly.
However, some adjustment must be made for the presence
of comorbidities, not directly accounted for by the score. It
has been suggested that both systems should be used
conjunctly. Either can successfully define low risk patients
not requiring hospitalization. In addition to the PSI, vital
sign and CURB-65 severity evaluation should be added. When
employing the CURB-65, an assessment of comorbid illness
and its stability should be added.74
Antibiotic treatment
Recent international guidelines have provided a framework
for initial empirical antibiotic selection in patients with CAP.
For outpatients with pneumonia, North American guide-
lines suggest the use of a macrolides, doxycycline, or a
fluoroquinolone agent, as appropriate empiric outpatient
treatment for low-risk patients (i.e., otherwise young
healthy individuals). Alternatives to these agents in low-
risk patients are amoxicillin/clavulanate and some second-
generation cephalosporins (e.g., cefuroxime, cefpodoxime,
or cefprozil).54,56 Recent European guidelines on lower
respiratory tract infection suggest tetracycline and amox-
icillin are antibiotics of first choice.In case of hypersensi-
tivity a newer macrolide like azithromycin, roxithromycin or
clarithromycin is a good alternative in countries with low
pneumococcal macrolide resistance.When there are clini-
cally relevant bacterial resistance rates against all first
choice agents, treatment with levofloxacin or moxifloxacin
may be considered.57 Oral treatment is generally suggested.
When treating CAP patients who require hospitalization,
consensus between guidelines from both sides of the
Atlantic is more consistent. Generally an association
between a beta-lactam (amoxicillin, amoxicillin/clavula-
nate, non-antipseudomonal II or III generation cephalospor-
in) plus a macrolide are suggested, with a respiratory
fluoroquinolone (levofloxacin, moxifloxacin) as alternative
monotherapy. In patients with risk factors for P. aeruginosa
pnemonia, combination therapy is generally advocated,
involving an antipseudomonal cephalosporin or acylureido-
penicillin/b-lactamase inhibitor or carbapenem, together
with ciprofloxacin.
Future strategies
Current treatment of pneumonia is largely based on timely
prescription of adequate antibiotic therapy. However,
antimicrobial treatments are hampered by the ever-increas-
ing problem of resistant strains, and the prospects for future
antibiotics preparations are gradually slimming. Alternative
strategies are therefore needed based on a better knowl-
edge of microbial pathogenetic mechanisms and a more
complete comprehension of host defense systems.
The complexity of the mechanisms and mediators
involved in inflammation and infection is increasingly being
unraveled, and the genetic regions controlling these factors
have been partly elucidated. Soluble and membrane-based
receptors have been identified that are capable of recogniz-
ing non-mammalian microbial motifs and mobilizing close to
instantaneous inflammatory reactions towards infection. Anincreasing number of peptides exerting antimicrobial activ-
ity are being recognized in airway secretions, associated
with chemokines, cytokines, proteinase inhibitors, and
surfactant proteins.
Genetic polymorphisms in genes for important inflamma-
tory molecules such as tumor necrosis factor, the inter-
leukin-1 family, interleukin-10, and angiotensin converting
enzyme, as well as molecules involved in innate immunity
antigen recognition, such as the mannose-binding lectin,
CD-14, and Toll-like receptors (TLRs), have been investi-
gated as potential modifiers in the natural history of sepsis
and pneumonia.75 Better knowledge of underlying genetic
traits may help identify patients at greater risk of severe
complications following infection. On the other hand, over-
activation of innate immune responses may be associated
with excessive inflammation and tissue damage such as may
be observed in sepsis.
In the future it may be possible to modulate the innate
immune response in order to downplay pathways leading to
tissue inflammation while enhancing mechanisms involved in
microbial elimination. Antimicrobial peptides (AMPs) pre-
sent in airway surface fluid are effector molecules of the
innate immunity with direct antimicrobial and mediator
function. They provide an initial host defense mechanism
that protects mucosal and dry epithelial surfaces of all
multicellular organisms. Several diseases in humans and
laboratory animals are characterized by impairment in the
function of an AMP.76 AMPs qualify as prototypes of
innovative drugs that might be used as antibiotics, anti-
polysaccharide drugs or modifiers of inflammation. Anti-
biotics based on these naturally occurring mammalian
peptides might elicit fewer allergic reactions compared to
conventional antibiotics. Synthetic analogs of AMPs may
evolve into novel and independent classes of antibiotics.77
Recently identified mammalian TLRs are capable of
distinguishing pathogen from self-components, triggering
cytokine production, and expressing co-stimulatory mole-
cules necessary for lymphocyte activation. Central to the
signaling cascade triggered by TLRs is the activation of
transcription factors such as nuclear factor kB (NF-kB) and
activator protein-1 (AP-1), key regulators of inflammatory
and immune responses.78 Given their central role in
activating and modulating host responses to infection, and
acting as a bridge between innate and adaptive immunity,
TLRs are being currently studied as potential therapeutic
targets. Soluble forms of TLRs may be made to bind and
neutralize natural ligands before they activate potent
proinflammatory responses in the host. Alternatively, anti-
bodies or molecules similar to natural ligands could be
employed in order to bind with TLR extracellular or
intracellular domains, though failing to activate intracel-
lular signaling. This may result in inhibition of pro-
inflammatory cascades initiated by TLRs, while retaining
TLR-related protective responses.79
Hepatocyte growth factor (HGF) is a is a heterodimeric
protein produced, among others, by lung fibroblasts and
macrophages, that promotes proliferation of type II epithe-
lial cells following lung injury, restoring alveolar and
bronchial epithelial integrity.80 Recently, HGF levels have
been tested in serum and exhaled breath condensate of
patients with pneumonia and other non-respiratory condi-
tions.81 During the first days of the infections, pneumonia
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followed by a marked drop at days 4–7 that persisted up to
4–6 weeks. Conversely, exhaled breath HGF levels, were also
higher than controls during the acute phase, but showed
non-drop through all the observation period, suggesting that
local production of this factor is active during pneumonia.
Future studies will be needed to determine whether local
inhalation of HGF may be considered ad an adjuvant
treatment, particularly in severe or complicated pneumonia
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